FUSID TABLETS

Pays: Israël

Langue: anglais

Source: Ministry of Health

Ingrédients actifs:

FUROSEMIDE

Disponible depuis:

TEVA ISRAEL LTD

Code ATC:

C03CA01

forme pharmaceutique:

TABLETS

Composition:

FUROSEMIDE 40 MG

Mode d'administration:

PER OS

Type d'ordonnance:

Required

Fabriqué par:

TEVA ISRAEL LTD, ISRAEL

Domaine thérapeutique:

FUROSEMIDE

indications thérapeutiques:

Edema associated with congestive heart failure, cirrhosis of the liver and renal disease, including the nephrotic syndrome. Adjunctive therapy in acute pulmonary edema. Treatment of hypertension.

Date de l'autorisation:

2021-06-30

Notice patient

.
ةيبناجلا ضارعلأا
لا .نيمدختسملا ضعب ىدل ةبيناج اضارعأ
صارقأ ديزوف لامعتسا ببسي دق ،ةيودلأا
عيمجك
.اهنم
ٍ
ّ
يأ نم يناعت
ّ
لاأ لمتحملا نمف .ة
ّ
يبناجلا ضارعلأا ةمئاق ةءارق دنع عزفت
:ةيلاتلا ضارعلأا دحأ نم تيناع اذإ ا
ً
روف ىفشتسملا ىلإ وأ بيبطلا ىلإ هجوتلا
بجي
ةيساسح ،دلجلا ر
ّ
شقت ،دلجلا باهتلا ،ةكح ،يدلج حفط ىلع
لمتشي دق ريطخ يسسحت لعف در
وأ ةرجنحلا وأ ناسللا ،نيتفشلا ،هجولا
مروت ،ىمح وأ ع
ّ
فستلا حيباصم وأ سمشلا ءوض هاجت
.علاتبلاا وأ سفنتلا يف ةبوعص
،ةيلسانتلا ءاضعلأاو فنلأا ،مفلا
،نينيعلا ،نيتفشلا لوح دلجلا ر
ّ
شقتي دق وأ تارثب لكشتت دق
.نوسنوج سنفيتس ةمزلاتم ىعدت ةلاح لكشت
نأ اهنأش نم ىمحو ازنولفنلإاب ةهيبش
ضارعأ
وأ لصافملا يف ملاآو ىمح ،حفط ىلإ يدؤي
دق يذلا ،
vasculitis ( ةيومدلا ةيعولأا باهتلا
يف مد دهاشت دق وأ اهيف ل
ّ
وبت يتلا تارملا ددع ر
ّ
يغي دق يذلا( ىلكلا باهتلا وأ )تلاضعلا
.)لحاكلا مروت لثم امروت ربتخت دق وأ
،ساعنلاب روعش ،ىمح نم يناعت دق .لوبلا
.)نيقاسلا يف ةيساسح وأ مروت ،ملأ ىلإ
يدؤت( ةيومد ةطلج
ة
ّ
يفاضإ ةيبناج ضارعأ
:ةيلاتلا ةيبناجلا ضارعلأا دحأ تربتخا
اذإ يلديصلا وأ بيبطلا غلابإ كيلع
:)نيلمعتسم 10 نيب نم دحاو لمع
َ
تسم نم رثكأ ىدل ثدحت( ادج ةعئاش ةيبناج
ضارعأ
مويسلاكلا ،رولكلا ،مويساتوبلا
،مويدوصلا لثم( مسجلا ي

Résumé des caractéristiques du produit

1
Fusid-tablets_SPC_Notification-worsing_12-2020_NS
SUMMARY OF PRODUCT CHARACTERISTICS
FUSID TABLETS
Tablets
1.
NAME OF THE MEDICINAL PRODUCT
Fusid tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 40 mg Furosemide
For the full list of excipients, see section Error! Reference source
not found..
3.
PHARMACEUTICAL FORM
White, round flat tablet, engraved "TEVA" on one side and bisected on
the other side of the
tablets.
4.
CLINICAL PARTICULARS
4.1.
THERAPEUTIC INDICATIONS
If gastrointestinal absorption is impaired or oral administration is
not practical for any reason,
and for patients in emergency clinical situations, Fusid is indicated
by the intravenous or the
intra-muscular route. Parenteral use should be replaced with oral
Fusid as soon as practical.
-
Treatment of edema associated with congestive heart failure, cirrhosis
of the liver and renal
disease, including the nephrotic syndrome.
-
Adjunctive therapy in acute pulmonary edema.
-
Treatment of hypertension.
4.2.
POSOLOGY AND METHOD OF ADMINISTRATION
_Posology _
Since furosemide is a potent diuretic which, if given in excessive
amounts, can lead to profound
diuresis with water and electrolyte depletion, careful medical
supervision is required. Dosage
should be adjusted to the individual needs of each patient.
_Adults _
_Edema:_ The usual initial dose is 20-80 mg/day administered as a
single dose. Usually, prompt
diuresis ensues. Depending on the response, a second dose should be
administered 6-8 hours
later. If the diuretic response is unsatisfactory, the dose should be
increased by increments of 20
or 40 mg, no sooner than 6-8 hours after previous dose, until the
desired diuretic effect has been
obtained. This individually-determined dose should then be
administered 1-2 times a day. In
patients with severe edema, dosage may be titrated up to 600 mg/day.
Mobilization of edema may be most efficiently and safely accomplished
with an intermittent
dosage schedule. Furosemide should be administered on 2-4 consecutive
days, each week.
With do